Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension

Abstract

As expected, CYP2D6 genotype-phenotype correlates with differences in metoprolol pharmacokinetics. However, there was no association between variable pharmacokinetics or CYP2D6 genotype and beta-blocker-induced adverse effects or efficacy.